1-9 of 9
Geraldine Ferron-Brady
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses for Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from Dreamm-9

Fernando Carreño, Morrys C Kaisermann, Jacqueline L Egger, Geraldine Ferron-Brady
Journal: Blood
Blood (2024) 144 (Supplement 1): 1974.
https://doi.org/10.1182/blood-2024-198720
Published: 2024
Journal Articles

Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3

Geraldine Ferron-Brady, Adekemi Taylor, Josh Kaullen, Kishore Polireddy, Astrid McKeown, Neal Sule, Herbert Struemper
Journal: Blood
Blood (2023) 142 (Supplement 1): 6730.
https://doi.org/10.1182/blood-2023-178026
Published: 2023
Journal Articles

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, Aránzazu Alonso Alonso, Hang Quach, Youngil Koh, Andreas Guenther, Chang-Ki Min, Xiaoou L. Zhou, Morrys Kaisermann, Lukasz M. Mis, Danaè Williams, Anne Yeakey, Geraldine Ferron-Brady, David J. Figueroa, Brandon E. Kremer, Ira Gupta, Wojciech Janowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 2738.
https://doi.org/10.1182/blood-2021-153315
Published: 2021
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Suzanne Trudel, MD, David Routledge, Kevin Song, MD, Hareth Nahi, MD, Sofia Paul, Josephine Khan, Maria Brouch, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Chris Shelton, Rocio Montes de Oca, PhD, L. Mary Smith, Ellie Im, Christoph M Ahlers, Elaine M Paul, Beata Holkova, Ira Gupta, MD, Brandon E. Kremer, MD PhD, Paula Rodriguez-Otero, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-139182
Published: 2020
Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay Nooka, MDMPH, Keith Stockerl-Goldstein, MD, Rafat Abonour, MD, Ryan Ramaekers, MD, Amit Khot, MD, Adam Forbes, MD, Cindy Lee, MD, Bradley Augustson, MBBS FRACP FRCPA, Andrew Spencer, Maria-Victoria Mateos, MD PhD, Bikramjit Chopra, PhD, Rachel Rogers, MS, Deborah A Smith, PharmD, Jacqueline Davidge, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Hang Quach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-139332
Published: 2020
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska
Journal: Blood
Blood (2019) 134 (Supplement_1): 1857.
https://doi.org/10.1182/blood-2019-129879
Published: 2019
Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Mark Dawson, MD PhD, Eytan M. Stein, MD, Brian J.P Huntly, Anastasios Karadimitris, PhD, Manali Kamdar, Carlos Fernandez de Larrea, Michael J. Dickinson, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Naval Daver, MD, Aristeidis Chaidos, MD PhD, Martin S. Tallman, MD, Raquel Jiménez, MD, Thierry Horner, PhD, January Baron, MS, John Brennan, Geraldine Ferron-Brady, Yuehui Wu, PhD, Natalie Karpinich, Brandon Kremer, Arindam Dhar, MBBS,MDPhD, Gautam Borthakur, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1377.
https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377
Published: 2017